Sacubitrilat

Sacubitrilat
Clinical data
Other namesLBQ657
ATC code
  • none
Identifiers
  • (2R,4S)-5-(4-Biphenylyl)-4-[(3-carboxypropanoyl)amino]-2-methylpentanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
PDB ligand
Chemical and physical data
FormulaC22H25NO5
Molar mass383.444 g·mol−1
3D model (JSmol)
  • C[C@H](C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O)C(=O)O
  • InChI=1S/C22H25NO5/c1-15(22(27)28)13-19(23-20(24)11-12-21(25)26)14-16-7-9-18(10-8-16)17-5-3-2-4-6-17/h2-10,15,19H,11-14H2,1H3,(H,23,24)(H,25,26)(H,27,28)/t15-,19+/m1/s1
  • Key:DOBNVUFHFMVMDB-BEFAXECRSA-N

Sacubitrilat (INN; or LBQ657) is the active metabolite of the antihypertensive drug sacubitril,[1] which is used in the treatment of heart failure.[2]

References

  1. ^ Solomon SD. "HFpEF in the Future: New Diagnostic Techniques and Treatments in the Pipeline". Boston. p. 48. Retrieved 2012-01-26.
  2. ^ "FDA approves new drug to treat heart failure". Food and Drug Administration. 7 July 2015. Archived from the original on July 7, 2015.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.